Neopharma Expands Into Biotechnology and Nanotechnology-Based Research and Development

DUBAI, UAE - Neopharma, the Abu Dhabi-based pharmaceuticals manufacturer, has ventured into biotechnology and nanotechnology-based research and manufacturing capabilities.

The announcement came at a press conference that was preceded by a ground breaking ceremony held under the patronage and in the presence of His Highness Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister for Higher Education and Scientific Research, and Chairman of Neopharma.

His Excellency Abdullah Humaid Al Mazroei, Vice-Chairman, and Dr. B R Shetty, Managing Director and CEO, Neopharma, said the AED250 million facilities will manufacture nutraceuticals, injectable preparations, topical applications, ophthalmic products and aerosols.

Manufacturing lines are concurrently being set up for a group of antibiotic drugs called ‘cephalosporins’, with separate areas allocated for both oral and injectable variations.

Dr. B. R. Shetty said: “Neopharma is aggressively pressing ahead with its organic growth initiatives. The immense support of Bank of Baroda, the lead financing partner, is a significant stimulus that complements our efforts.

“The new facilities will mark our foray into high-technology based research and development (R&D). In the long-term, our initiatives will contribute to creating suitable opportunities for students in the country and help create a professional talent pool.”

Neopharma’s state-of-the-art facilities that are expected to begin operations within 14 months will be designed on the guidelines recommended by US FDA.

About Neopharma:

Neopharma is a premier pharmaceuticals manufacturing company based in Abu Dhabi. Set up in October 2003, Neopharma manufactures a wide range of products including antibiotics, analgesics, respiratory medicines, antihistamines, as well as medications for cardiovascular conditions and diabetes. A robust R&D centre, hi-tech manufacturing and quality embedded operations make the company a manufacturer of world-class pharmaceutical products.

Neopharma has received the prestigious Mohammed bin Rashid Al Maktoum Award in the manufacturing category and is also the recipient of the current European Good Manufacturing Practice Guidelines Certification from Belgium. The company has received the ISO 9001, ISO 14,001 and OHSAS 18,001 certifications for integrated management system encompassing quality, environment and safety standards. These accolades reflect Neopharma’s penchant for quality - a key driver for generic pharmaceutical business.

Steered under the visionary leadership of the Board of Directors and Dr. B.R. Shetty, Neopharma is all set to make a foray into the healthcare of the future - biotechnology and nanotechnology based products

For further information: Zeba AhmadJiWin Tel: +9714-361-3590 (direct) e-mail: Zeba.Ahmad@jiwin.ae

Source: Neopharma

For further information: Zeba AhmadJiWin, Tel: +9714-361-3590 (direct), e-mail: Zeba.Ahmad at jiwin.ae